Toremifene in Treating Patients With Desmoid Tumors
Launched by ADVOCATE LUTHERAN GENERAL HOSPITAL · Apr 21, 2004
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
OBJECTIVES: I. Determine the efficacy of toremifene in terms of tumor response rate and symptom relief in patients with desmoid tumors. II. Determine the safety of this regimen in these patients. III. Determine the quality of life of patients treated with this regimen.
OUTLINE: Patients are stratified by gender. Patients receive oral toremifene daily until complete or maximal response in the absence of disease progression or unacceptable toxicity. Patients achieving maximal response undergo complete resection of all lesions, if feasible. Nonsurgical candidates with severe or life-threateni...
Gender
ALL
Eligibility criteria
- • DISEASE CHARACTERISTICS: Histologically proven primary or recurrent desmoid tumor Unresectable and symptomatic or progressive disease OR Disease for which a mutilating surgery would be required for complete resection Bidimensionally measurable or clinically evaluable disease
- • PATIENT CHARACTERISTICS: Age: 16 and over (no prepubertal patients) Performance status: 0-2 Life expectancy: More than 2 months Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 mg/dL Transaminases no greater than 3 times upper limit of normal (ULN) Alkaline phosphatase no greater than 3 times ULN Renal: Not specified Cardiovascular: No history of deep vein thrombosis Other: Not pregnant Fertile patients must use effective barrier contraception
- • PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: No concurrent dexamethasone for antiemesis No other concurrent hormonal therapy, including hormonal contraceptives Radiotherapy: Not specified Surgery: See Disease Characteristics
About Advocate Lutheran General Hospital
Advocate Lutheran General Hospital is a leading healthcare institution committed to advancing medical research and improving patient care through innovative clinical trials. As part of the Advocate Aurora Health system, the hospital leverages its state-of-the-art facilities and a multidisciplinary team of healthcare professionals to conduct high-quality research across various therapeutic areas. With a focus on patient safety and ethical standards, Advocate Lutheran General Hospital aims to contribute significantly to the development of new treatments and therapies, enhancing health outcomes for the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Park Ridge, Illinois, United States
Patients applied
Trial Officials
Brian L. Samuels, MD
Study Chair
Advocate Lutheran General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials